This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang-Johanning, F. Articles by Curiel, D. T. Search for Related Content PubMed PubMed Citation Articles by Wang-Johanning, F. Articles by Curiel, D. T.

Intracellular Expression of a Single-Chain Antibody Directed against Human Papillomavirus Type 16 E7 Oncoprotein Achieves Targeted Antineoplastic Effects¹

Gene Therapy Program, Comprehensive Cancer Center [F. W-J., J. G., C. R., D. T. C.], Division of Neurosurgery [G. Y. G.], and Departments of Obstetrics and Gynecology [R. D. A.] and Pathology [G. P. S.], University of Alabama at Birmingham, Birmingham, Alabama 35294

Human papillomavirus type 16 (HPV16) E7 is a viral oncoprotein that is believed to play a major role in cervical neoplasia. Anti-HPV16 E7 intracellular single-chain antibodies (scFvs) were constructed to down-regulate HPV16 E7 oncoprotein in HPV DNA-containing cell lines. In these studies, we transfected anti-E7 scFvs into the HPV16-positive human cervical carcinoma cell lines CaSki and SiHa and tested them for their ability to inhibit cell proliferation and alter the level of HPV16 E7 oncoprotein. Our results showed that anti-HPV16 E7 scFvs inhibited cell proliferation by >85% in CaSki cells and by 95% in SiHa cells. E7 oncoprotein was down-regulated by anti-HPV16 E7 scFv, and its expression was inversely related to the amount of scFv transfected. However, there were no effects of transfecting scFvs alone in HPV-negative cell lines. These results imply that anti-HPV16 E7 scFvs only have specific anti-HPV16 E7 effects on cell proliferation and on the synthesis of virally encoded proteins in HPV-positive cell lines. Thus, transfection of HPV16 E7-positive tumors with antigen-specific scFvs may be a viable strategy for cervical cancer gene therapy.

¹ This work was supported by National Cancer Institute Grant RO1 CA-68245.

² To whom requests for reprints should be addressed, at University of Alabama at Birmingham, 1824 6th Avenue South, WTI 620, Birmingham, AL 35294. Phone: (205) 934-8627; Fax: (205) 975-7476; E-mail: david.curiel@ccc.uab.edu.

Received 10/27/97. Accepted 3/ 4/98.

This article has been cited by other articles:

				F. Wang-Johanning, L. Radvanyi, K. Rycaj, J. B. Plummer, P. Yan, K. J. Sastry, C. J. Piyathilake, K. K. Hunt, and G. L. Johanning Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients Cancer Res., July 15, 2008; 68(14): 5869 - 5877. [Abstract] [Full Text] [PDF]

				K. Nakamura, A. Hongo, J. Kodama, Y. Miyagi, M. Yoshinouchi, and T. Kudo Down-Regulation of the Insulin-like Growth Factor I Receptor by Antisense RNA Can Reverse the Transformed Phenotype of Human Cervical Cancer Cell Lines Cancer Res., February 1, 2000; 60(3): 760 - 765. [Abstract] [Full Text]

				P. M. O'Brien, R. Aitken, B. W. O'Neil, and M. S. Campo Generation of native bovine mAbs by phage display PNAS, January 19, 1999; 96(2): 640 - 645. [Abstract] [Full Text] [PDF]